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ABSTRACT
Background: Gastrointestinal stromal tumors (GISTs) are characterized by 
oncogenic KIT mutations that cluster in two exon 11 hotspots. The aim of this study 
was to develop a single, sensitive, quantitative digital droplet PCR (ddPCR) assay 
for the detection of common exon 11 mutations in both GIST tumor tissue and in 
circulating tumor DNA (ctDNA) isolated from GIST patients’ plasma.
Methods: A ddPCR assay was designed using two probes that cover both hotspots. 
Available archival FFPE tumor tissue from 27 consecutive patients with known KIT 
exon 11 mutations and 9 randomly selected patients without exon 11 mutations were 
tested. Plasma samples were prospectively collected in a multicenter bio-databank 
from December 2014. ctDNA was analyzed of 22 patients with an exon 11 mutation 
and a baseline plasma sample.
Results: The ddPCR assay detected the exon 11 mutation in 21 of 22 tumors with 
exon 11 mutations covered by the assay. Mutations in ctDNA were detected at baseline 
in 13 of 14 metastasized patients, but in only 1 of 8 patients with localized disease. In 
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serial plasma samples from 11 patients with metastasized GIST, a decrease in mutant 
droplets was detected during treatment. According to RECIST 1.1, 10 patients had 
radiological treatment response and one patient stable disease.
Conclusion: A single ddPCR assay for the detection of multiple exon 11 mutations 
in ctDNA is a feasible, promising tool for monitoring treatment response in patients 
with metastasized GIST and should be further evaluated in a larger cohort. 
INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are rare 
malignancies of the gastrointestinal tract [1]. GIST is 
known to have driver single nucleotide variants, deletions 
and insertions (further referred to as mutations) in genes 
encoding the tyrosine kinase receptors KIT and PDGFRα. 
These occur in respectively 80% and 10% of GIST patients 
[2, 3]. In untreated GIST patients, the most frequent 
mutations are in KIT exon 11 (70%) coding for the juxta-
membrane domain, and KIT exon 9 (10% of patients), 
coding for the extracellular domain of the receptor [4]. 
Around 80% of the mutations in KIT exon 11 cluster in 
two hotspot regions of approximately 25 base pairs within 
a 100 base-pair range of each other [5]. 
Therapy consists of surgery and/or treatment with 
one of several selective tyrosine kinase inhibitors (TKIs). 
Adjuvant treatment with a TKI is based on Miettinen’s 
risk classification which takes the size of the tumor, 
location and mitotic index into account [6]. Independently 
of the Miettinen classification, there is also a difference 
in recurrence risk between GISTs with different KIT and 
PDGFRα mutations [7]. First line treatment for locally 
advanced or metastatic GISTs consists of imatinib (400 mg 
daily), a selective inhibitor of the KIT tyrosine kinase [8]. 
Almost all patients with exon 11 mutated GIST respond 
to imatinib treatment, whereas exon 9 mutated GISTs 
have lower response rates. A large meta-analysis of 1,640 
patients showed that bi-daily imatinib 400 mg is more 
effective than once daily dosing in KIT exon 9 mutated 
patients [9]. Resistance to imatinib treatment is usually the 
result of one or multiple secondary mutations that develop 
during treatment [10, 11]. 
Second and third line treatment, with respectively 
sunitinib and regorafenib, also showed differential 
response rates that correlated with the primary mutational 
status of the tumor [12–14]. 
Molecular diagnostic testing of relevant predictive 
biomarkers, including KIT and PDGFRα, is becoming 
routine practice in clinical decision-making. Mutation 
detection is routinely performed on pre-treatment tumor 
biopsies or resection specimens. For the detection of 
mutations a variety of methods are used, including as 
Sanger sequencing, pyro-sequencing, next generation 
sequencing (NGS) and high-resolution-melting (HRM) 
analysis with reflex sequencing [15]. These techniques are 
expensive, time consuming and require sufficient amounts 
of DNA (>100 ng) and a sufficient percentage of neoplastic 
cells (>5–20%). In some cases, no representative tumor 
material is available for molecular testing. Alternative 
methods for mutation detection, ideally also allowing 
serial non-invasive measurements, are urgently needed. 
Interestingly, recent advantages in molecular 
pathology enable the detection of tumor specific mutations 
in circulating tumor DNA (ctDNA) extracted from blood 
plasma [16]. CtDNA can be used to define targets for 
selective therapy in both untreated and TKI-resistant non-
small-cell-lung-cancer (NSCLC) tumors [17, 18]. The 
detection of mutations in ctDNA as a predictive biomarker 
has been reported in both metastatic breast cancer (MBC) 
[19] and metastatic colorectal cancer (CRC) [20]. Finally, 
mutation testing in ctDNA allows monitoring of TKI 
treatment response, where an increase in mutations could 
predict recurrence or disease progression [18]. Sporadic 
reports describe the use of ctDNA to detect mutations in 
GIST patients [21–24]. 
ctDNA is present in low amounts in plasma within 
a much more abundant background of non-tumor DNA 
(wild type) and is varying based on tumor type [25]. 
Highly analytical sensitive methods are used to detect 
ctDNA in plasma, these include BEAMing [26] and 
digital droplet PCR (ddPCR) [26, 27]. Both BEAMing 
and ddPCR assays require the use of a separate assay for 
each tumor specific mutation. In general practice, based on 
the mutation detected in the tumor sample, a unique assay 
for the specific mutation is designed. Recently, the use of 
a single ddPCR assay to simultaneously detect various 
EGFR-exon 19 deletions in the plasma of NSCLC patients 
was reported [28].
Given the long disease course of GIST patients 
and the multiple therapeutic options depending on 
mutational status of the tumor, a non-invasive test that 
can easily assess the presence of mutations is especially 
interesting for this patient group. Therefore, the aim of 
this exploratory study was to develop a ddPCR assay to 
detect most common exon 11 KIT mutations in. For the 
validation of this drop-off ddPCR assay we tested 36 
formalin fixed paraffin embedded (FFPE) pre-treatment 
biopsies of patients with GIST previously tested for 
mutations using sequencing. To investigate the utility 
of this assay for detecting exon 11 mutations in ctDNA, 
plasma from 22 GIST patients was analyzed at baseline 
and at various time points during TKI treatment.
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RESULTS
Mutations in KIT exon 11 in GIST FFPE tumor 
tissue detected using the ddPCR drop-off assay 
27 tumors with KIT exon 11 mutations were 
included, 17 tumors had a deletion, 1 a duplication, 4 a 
deletion/insertion and 5 had single nucleotide variants 
(SNV) as previously identified by sanger sequencing 
or NGS. Seventeen mutations cluster in hotspot 1, 6 in 
hotspot 2, one tumor had a deletion affecting both hotspots 
(sample 12) and in 3 tumors the deletion did not occur 
within the hotspots (samples 25, 26, 27, Figure 1). Using 
the drop-off assay, a KIT mutation was detected in 21/27 
tumors (see examples in Supplementary Figure 1). Tumor 
18 had a duplication and was considered negative in 
the drop-off assay, however a typical pattern of droplet 
distribution was seen (Supplementary Figure 2). In 4 of the 
5 negative tumors (20, 25, 26 and 27) the deletion did not 
allow annealing of the PCR-primer and therefore a PCR-
product could not be generated (true negative tumors). 
Tumor 21 carried a SNV within the detection range of 
probe 2 and was the only true false-negative tumor. Of 22 
tumors with mutations in KIT exon 11 covered by the drop-
off assay, 21 tumors were positive resulting in a sensitivity 
of 95%. Analysis of the allelic frequency of mutant alleles 
versus wild type alleles of ddPCR corroborated the NGS 
results (Table 1). As a negative control, 9 tumors without 
KIT exon 11 mutations were analyzed. These consisted of 
4 tumors with a PDGFRα mutation, 2 with a KIT exon 
9 mutation and 3 without any KIT/PDGFRα mutations. 
All control GIST samples were negative resulting in a 
specificity of 100% (Supplementary Figure 3).
Tumor and treatment characteristics 
Plasma samples taken before start of TKI treatment 
(baseline) of 22 patients with GIST were analyzed. 
Of these 22 patients, 14 had metastatic disease and 8 
localized disease. Four patients with localized disease 
were planned to start with imatinib 400mg treatment in 
a neo-adjuvant setting (patient 7, 9, 13 and 17) and four 
patients underwent primary surgery. Samples of patients 
with metastatic disease were taken before start of a new 
line of TKI treatment (Table 2). 
Detection of exon 11 mutations in ctDNA with 
the drop-off ddPCR assay 
KIT exon 11 mutations were detected in the baseline 
plasma ctDNA from 13/14 patients with metastasized 
disease (Table 2). Pre-treatment tumor DNA available 
for 12 of these patients tested positive using the drop-off 
ddPCR assay. Plasma from one patient (patient 6) with 
metastasized disease had no detectable mutant ctDNA 
while a KIT mutation was detected in the pre-treatment 
tumor biopsy. In plasma ctDNA collected before start of 
treatment in eight patients with localized disease and a 
tumor KIT exon 11 mutation, only one patient (sample 7) 
had a detectable mutation in the ctDNA (Table 3).
To exclude that the lack of detectable ctDNA 
mutations was due to low sensitivity of the drop-off 
Figure 1: Location of KIT exon 11 mutations in GIST tumour samples as tested with Sanger sequencing or NGS. The 
mutations are displayed relative to the actual position of the Forward and Reverse primers, the two probes (I and II) and PCR product. Type 
of mutations: red = deletion, grey = substitution, blue = deletion/insertion, orange = duplication.
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ddPCR assay, tumor and plasma samples collected from 
two patients with metastasized disease (patient 3 and 
15) during treatment with a TKI were also tested with 
a specific ddPCR mutation assay. As shown in Table 4, 
the mutant fractional abundance is comparable between 
the ddPCR and the specific assay. In addition, plasma 
samples from three different patients were tested using 
the highly sensitive analytical L-PCR technique for 
the detection of specific KIT exon 11 mutations earlier 
described [22] (Table 5). For this analysis, we selected 
eight plasma samples from three patients with different 
KIT exon 11 mutations tested with the drop-off ddPCR 
assay. Low level mutant frequencies detected with the 
L-PCR technique (<0.1%) were also positive in the drop-
off samples. Of the samples that tested negative using the 
drop-off assay, 4/5 were also negative using the L-PCR 
technique. 
The detection of mutations in plasma ctDNA at 
different time points during treatment
In order to monitor the presence of mutations after 
start of TKI treatment compared to baseline samples, serial 
plasma samples of 11 patients with metastatic disease using 
Table 1: Tested patients with drop-off assay in relation to NGS results
Allelic frequency Mutation
Patient
Mutant Mutant
in probe area Mutation
ddPCR NGS
1 44,00% 38% 1 KIT Exon 11 c.1667_1669del
2 58,00% 61% 1 KIT Exon 11 c.1669T>C
3 53,00% 59% 2 KIT Exon 11 c.1727_1729del
4 41,00% 41% 1 KIT Exon 11 c.1671_1676del
5 30,00% 27% 2 KIT Exon 11 c.1726_1728del
6 34,00% 38% 2 KIT Exon 11 c.1727-1729delTTC
7 42,00% 38% 1 KIT Exon 11 c.1676T>A
8 45,00% 45% 1 KIT Exon 11 c.1669_1674del
9 54,00% 55% 1 KIT Exon 11 c.1671_1672delinsTG
10 40,00% 38% 1 KIT Exon 11 c.1669_1674del
11 83,00% 80% 1 KIT Exon 11 c.1679_1680delinsAG
12* 22,00% 28% 1,2 KIT Exon 11 c.1673_1717del
13 24,00% 45% 1 KIT Exon 11 c.1662_1674delinsGGAAGAA
14 88,00% 91% 1 KIT Exon 11 c.1669_1674del
15 35,00% 34% 1 KIT Exon 11 c.1676T>A
16 35,70% 57% 1 KIT Exon 11 c.1669_1674delTGGAAG
17 22,30% 25% 1 KIT Exon 11 c.1669_1674del
18$ 0,00% 11% 2 KIT Exon 11 c.1719_ 1751dup
19 43,60% 44% 1 KIT Exon 11 c.1669T>C
20& 0,00% 79% 1 KIT Exon 11 c.1650_1673delinsCCTTCG
21 0,00% Sanger 2 KIT Exon 11 c.1727 T>C
22 95,00% 86% 1 KIT Exon 11 c.1668_1679del
23 41,00% Sanger 2 KIT Exon 11 c.1735_1737del
24 47,00% Sanger 1 KIT Exon 11 c.1674_1715del
25& 0,00% 41% 0 KIT Exon 11 c.1655_1660delTGTATG
26& 0,00% 56% 0 KIT Exon 11 c.1649_1663del
27& 0,00% 44% 0 KIT Exon 11 c.1649_1663del
Detection of mutations in KIT with the ddPCR assay of pre-treatment tumor samples compared to the mutant allelic frequency as determined with NGS.  
*despite a deletion partially overlapping with both hotspot areas, a signal was observed with probe 2;  
&deletion located in the forward primer annealing site precluding amplification of the mutated allele;  
$duplication considered negative, however a typical pattern of droplet distribution was seen.  
For representative examples see Supplementary Figure 1.
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the ddPCR drop-off assay were available and analyzed. 
The analysis of plasma samples at 2–3 weeks after start 
therapy revealed an increase in fractional abundance in 5 
out of 11 patients (Figure 2, Supplementary Table 1). In 
all available plasma samples obtained six weeks after start 
of treatment the fractional abundance decreased below the 
levels observed at baseline or the 2–3 weeks after start of 
treatment sample. In agreement with the loss of detection 
of mutant DNA, ten patients showed a tumor response and 
one patient stable disease (no. 45) on treatment with TKI 
according to the first radiological evaluation performed 
approximately 3 months after start of therapy. 
Table 2: Plasma ctDNA analysis with drop-off ddPCR assay of GIST patients with metastasized disease
Patient
Primary 
GIST 
location
Prior  
treatment
New 
treatment Mutation  
Fractional 
abundance
3 Stomach Imatinib Sunitinib KIT exon 11 c.1727_1729del 12,00%
4 Stomach - Imatinib KIT exon 11 c.1671_1676del 0,40%
6 Small bowel Imatinib Sunitinib
Regorafenib KIT exon 11 c.1727-1729del 0,00%
11 Small bowel - Imatinib KIT exon 11 c.1679_1680delinsAG 0,10%
14 Stomach - Imatinib KIT exon 11 c.1669_1674del 14,20%
15 Small bowel - Imatinib KIT exon 11 c.1676T>A 1,00%
16 Stomach - Imatinib KIT exon 11 c.1669_1674del 1,40%
39 Small bowel
Imatinib 
Sunitinib 
Regorafenib
-
KIT exon 11 c.1676_1684del 3,00%
40 Small bowel - Imatinib KIT exon 11 c.1668_1717delinsACCTT 7,00%
41 Stomach - Imatinib KIT exon 11 c.1671_1715del 8,70%
42 Stomach Imatinib Masitinib KIT exon 11 c.1670_1675del 0,90%
43 Small bowel - Imatinib KIT exon 11 c.1676T>A 0,40%
44 Small bowel - Imatinib KIT exon 11 c.1665_1676del 0,90%
45 Stomach Imatinib Sunitinib KIT exon 11 c.1674_1695del 3,10%
Plasma samples were collected before start of a new line of TKI treatment. Pre-treatment primary tumors of 12 patients 
tested positive with the drop-off assay (patient 3–16 see Table 1, patient 39–43 data not shown, patient 44 and 45 were not 
tested due to lack of tumors tissue). The fractional abundance was determined using DNA input representing 4 ml plasma.
Table 3: Plasma ctDNA analysis of GIST patients with localized/locally advanced disease
Patient
Primary 
GIST 
location
Disease status Mutation  Mutant allelic frequency
7 Rectum Localized KIT exon 11 c.1676T>A 1,95%
9 Stomach Localized KIT exon 11 c.1671_1672delinsTG 0,00%
10 Stomach Localized KIT exon 11 c.1669_1674del 0,00%
12 Stomach post-surgery KIT exon 11 c.1673_1717del 0,00%
13 Stomach Localized KIT exon 11 c.1662_1674delinsGGAAGAA; 0,00%
17 Stomach Localized KIT exon 11 c.1669_1674del 0,00%
19 Small bowel Localized KIT exon 11 c.1669T>C 0,00%
37 Stomach Localized KIT exon 11 c.1679 T>A 0,00%
Primary tumors of 7 of these patients were tested positive with the assay (patient 7–19 see Table 1, patient 37 data not 
shown, tumor of patient 38 was not positive). Samples were taken before start of any treatment.
Oncotarget13875www.impactjournals.com/oncotarget
DISCUSSION
In this study, an in-house designed single ddPCR 
assay was able to detect multiple mutations in KIT exon 
11 with high sensitivity (95%) and specificity (100%) in 
tumor biopsies of patients with GIST. Sensitivity of the 
assay for all known KIT exon 11 mutations in GIST is 
lower than 95% since the designed assay covers 80% of 
the described KIT exon 11 mutations (in the described 
cohort 21/27 mutations were detected resulting in a 
sensitivity of 77%). For LOB analysis 5 plasma samples 
from healthy individuals and 5 normal FFPE samples were 
analyzed. No false positive droplets were detected in the 
ddPCR analysis of these samples. As expected, due to 
the quality of the FFPE material, highly damaged DNA 
as well as artifactual C>T transitions the ddPCR resulted 
in a reduced separation of wild type droplets [29]. This 
should be taken into account when interpreting test results. 
However, for mutation screening in freshly-processed cell-
free plasma DNA, the separation between drop-off and 
wild type droplets was excellent in all samples tested in 
this study. Despite a very good LOB and a high sensitivity 
of 0.1%, the maximum sensitivity that can be obtained is 
limited by the input of the total number of copies of a 
genome. As in plasma samples the total amount of DNA 
is often close to 2ng, this input of DNA would result in a 
sensitivity of 1%. 
This assay enabled the detection of low-level copy 
mutations and the identification of mutations in 12 of 
13 cell-free plasma samples of patients with metastatic 
Table 4: Correlation between the ddPCR with a mutation-specific assay and the drop-off assay
Patient Type Fractional abundance drop-off probe
Fractional abundance mutant 
specific probe
Mutation
3 Tumor 53% 48% c.1727_1729del
3A Plasma 12,02% 11,60% c.1727_1729del
3B Plasma 8,70% 7,20% c.1727_1729del
3C Plasma 0,70% 0,72% c.1727_1729del
15 Tumor 35% 33% c.1676T>A
15A Plasma 0,90% 1,02% c.1676T>A
15B Plasma 5,50% 4,90% c.1676T>A
15C Plasma 0,00% 0,00% c.1676T>A
Two tumor samples and six plasma samples of two patients with metastasized disease were tested with a probe specifically 
designed for the mutation. *A = before start of treatment, *B = after two weeks of treatment, *C = after 6 weeks of treatment.
Table 5: Comparison of L-PCR with ddPCR
Patient mutation
L-PCR 
Mutation/wild 
type %
ddPCR  
Mutation/
wild type % 
Disease  
status
7A c.1676T>A 0,0019 1,95 Localized Before start of treatment
7B c.1676T>A 0,0024 0 Localized 1 week treatment imatinib
7C c.1676T>A 0 0 Localized 4 week treatment imatinib
10A c.1669_1674del 0 0 Localized Before surgical treatment
10B c.1669_1674del 0 0 Localized 3 days after surgery
15A c.1676T>A 0,0015 0,94 Metastasized Before start of treatment
15B c.1676T>A 0,0012 5,60 Metastasized 2 weeks treatment with imatinib
15C c.1676T>A 0 0 Metastasized 6 weeks treatment with imatinib
To evaluate the sensitivity of our assay, multiple samples of three patients were analysed with the earlier described L-PCR 
technique. Quantitative L-PCR analysis was performed on 1 ml plasma as reported previously [Maier et al., 2013]. Four 
samples were scored low-level positive (<0,1% mutant/wild type ratio). When looked at positive/negative samples the results 
where –except for sample 7B- comparable with the ddPCR assay. 
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disease at baseline. DdPCR is relatively cheap and has a 
short turn-around time. Since the probe does not detect 
specific mutations in exon 11 of the KIT gene, the drop-off 
ddPCR assay is especially suitable for predictive testing 
of GIST in case not enough tissue or neoplastic cells are 
available for NGS analysis or for monitoring treatment 
response in ctDNA. 
Mutation testing in ctDNA might be an alternative 
source for tissue biopsies particular when no biopsies or 
biopsies with insufficient neoplastic cells percentages 
for molecular profiling are available [30]. In addition, 
mutation analysis of ctDNA during treatment has been 
reported as a new tool for monitoring treatment response 
since the amount of ctDNA correlates with the volume 
of vital tumor tissue [31]. Circulating DNA in the cell-
free plasma fraction originates from many different 
cells including lymphocytes and neoplastic cells [32]. 
Their nuclear and mitochondrial DNA is released into 
the circulation in the process of cellular destruction by 
apoptosis or necrosis [25]. Therefore, ctDNA in cell-
free plasma is a very low fraction of the total amount 
of circulating DNA. For the detection of mutations in 
ctDNA in a high background of total plasma DNA, various 
detection assays with high analytical sensitivity have been 
reported including digital PCR, BEAMing, sequencing 
based methods, Ligand PCR, ARMS-PCR and PNA-
clamping PCR [33]. Because the analytical sensitivity of 
NGS is around 1–5% and also requires high amounts of 
input DNA, NGS is at present not suitable for mutation 
screening in ctDNA from plasma in malignancies with low 
abundance of ctDNA. On the other hand, the ddPCR has 
been reported as a quantitative, accurate assay with high 
Figure 2: Detection of KIT exon 11 mutations using the ddPCR drop-off assay in ctDNA in patients with metastasized 
GIST at baseline (before start TKI-treatment) and 2–6 weeks after start of treatment. Mutation frequency is expressed as 
fractional abundance in % (see Supplementary Table 1). Twelve patients with metastasized GIST with both a baseline plasma sample as 
well as at least one sample collected 2–6 weeks after staring TKI treatment were selected. Both pre-treatment FFPE DNA (Table 1) and 
baseline plasma samples (Table 2) were tested with the same ddPCR. Patient 39 and 41 (Table 3) were not included since no follow-up 
plasma samples were available.
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analytical sensitivity [34]. Sensitivities of 0.005–0.1% 
for EGFR-T790M (own unreported data, [28]), 0,1% and 
0,5% for ALK-C1156Y and ALK-G1269A in lung cancer 
[35] and 0.025% for KRAS in CRC [36] are reached.
To the best of our knowledge, this is the first time 
a single ddPCR assay to detect multiple KIT exon 11 
mutations in tumor tissue and ctDNA of patients with 
GIST has been reported. Few other studies have described 
the use of mutational analysis of ctDNA in GIST. In a 
recent study, using a NGS platform after enrichment 
PCR with PNA probes, KIT mutations were detected in 
the plasma of 13 out of 18 patients with localized gastric 
GIST [37]. With the allele specific ligation PCR assay KIT 
mutations were found in 9 out of 18 patients with active 
disease, furthermore mutations at low levels were detected 
in 6 out of 20 patients in complete remission [22]. Another 
study using BEAMing detected primary mutations in 5 
out of 30 patients with TKI-refractory GIST (17%) [23]. 
Both BEAMing and the allele specific ligation PCR assay 
require the generation of specific primers/probes for each 
genomic KIT mutation. In GIST patients with localized 
disease and proven KIT mutations in the pre-treatment 
biopsy, our assay detected the mutations in the baseline 
plasma DNA in only 1 of 8 cases. An explanation for this 
discrepancy is that localized tumors may not actively shed 
tumor DNA into the circulation. In other malignancies an 
association was reported with the detection of mutations 
in plasma and advanced stage disease [38].
The ddPCR drop-off assay was previously described 
for the detection of various clinical-relevant deletions 
in exon 19 of the EGFR gene in lung cancer [28]. This 
ddPCR drop-off del 19 assay showed a sensitivity of 5–50 
mutant copies in a background of 10,000 wild type copies 
which is similar to our observed sensitivity for the ddPCR 
drop-off assay for KIT exon 11 mutations. 
In the analysis of serial ctDNA samples, an evident 
rise of fractional abundance was seen after initiation of 
treatment. We hypothesized that the rise of mutational 
level could be due to increased cell death induced therapy 
initiation. This early response is not reported in other 
malignancies treated with TKI [39]. Our result implies 
that treatment response can be monitored by using this 
ddPCR assay in cell-free plasma. Similar observations 
were also reported using quantitative L-PCR in 5 patients 
with advanced GIST [22]. Monitoring of treatment 
response has also been reported in anti-EGFR treated 
CRC using KRAS mutations [40], TKI-treated lung cancer 
for EGFR del19/L858R [41], BRAF mutated melanoma 
[42] and gynecologic malignancies [43] and detection of 
progression on primary TKI in ctDNA has been reported 
in EGFR mutated NSCLC [44] and CRC [45].
Since tumors evolve during treatment and 
secondary mutations can cause therapeutic resistance, a 
new biopsy can be required during treatment to define 
the actual mutational status [46]. This has recently been 
demonstrated in patients with NSCLC during treatment 
with EGFR-TKI. The EGFR TKI-resistance mutation 
T790M was detected in ~70% of plasma ctDNA of 
patients with advanced disease who had acquired TKI-
resistance [47]. These resistant mutations could be missed 
by conventional tissue biopsy due to tumor heterogeneity 
[48]. In addition, repeated tumor biopsies have risks e.g. 
bleeding, perforation and infection. Thus, there is a need 
for less invasive techniques that provide information 
about mutational status of tumors and that can be easily 
performed at different time points during treatment. The 
detection of primary and secondary resistant mutations in 
ctDNA cannot be used only to monitor recurrences before 
clinical manifestation, but might also warrant a different 
therapeutic approach. Recently, the FDA approved the 
detection of the EGFR TKI resistant T790M mutation in 
plasma (June 1, 2016) as a marker for a second generation 
EGFR TKI specifically inhibiting the T790M mutation 
[49]. Similarly, in GIST, resistance develops during 
imatinib treatment. In 50% of patients with progressive 
disease, a secondary mutation, besides the primary KIT 
mutation, is detected [50]. Treatment response to standard 
second line therapy, sunitinib, differs between patients 
with secondary KIT exon 13/14 or exon 17/18 mutations 
[51]. The detection of secondary mutations in plasma was 
reported in 4 patients using pre-amplification and NGS. 
Mutant alleles were detected in a range of 0.010–9.385% 
[24]. In a study using BEAMing secondary mutations were 
detected in 11 out of 30 patients (41%) [23]. Therefore, the 
implementation of ddPCR (or other sensitive) detection 
assays to identify resistant KIT mutations in plasma 
ctDNA is warranted for the development of more optimal 
treatment strategies in patients with GIST treated with 
TKIs.
The detection of multiple KIT exon 11 mutations 
with a single ddPCR assay has high sensitivity and 
specificity. It is suitable for predictive testing of GIST in 
case not enough tissue or neoplastic cells are available 
for routine NGS analysis in FFPE tissue. This technique 
can be easily performed, is cost-effective and has a short 
turn-around-time. Therefore, this ddPCR assay might be 
especially suitable for treatment response monitoring by 
ctDNA analysis in plasma. Our study will be extended 
to include the monitoring of early progression based on 
ctDNA, which may guide early treatment adaptations.
MATERIALS AND METHODS
Study design 
The reported work is part of an open-label, non-
randomized, non-interventional, explorative multicenter 
study aiming to detect the most frequently occurring 
KIT exon 11 mutations using a single ddPCR assay. 
The assay was first tested on archival formalin-fixed 
paraffin-embedded (FFPE) tumor tissue stored at the 
University Medical Centre Groningen (UMCG). After 
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validation with tumor tissue, this assay is tested in 
prospectively collected plasma samples from 22 GIST 
patients before and during treatment with a TKI. These 
22 patients were treated in one of the five hospitals in 
the Dutch GIST consortium (Antoni van Leeuwenhoek, 
Amsterdam; Leiden University Medical Centre, Leiden; 
Erasmus University Medical Centre, Rotterdam; Radboud 
University Medical Centre, Nijmegen; University Medical 
Centre Groningen, Groningen). 405 plasma samples of 
140 GIST patients before or during treatment with a TKI 
have been prospectively collected (Dec 2014 - Sept 2016). 
Treatment, follow-up and response evaluation by CT 
according to RECIST 1.1, were performed according to 
(inter)national guidelines. Plasma samples were available 
before start and at multiple time points after start of a TKI 
for 8 patients with localized GIST and 14 patients with 
metastasized GIST. All patients had measurable disease 
before collection of the first plasma sample and received 
systemic treatment during the study period. Plasma 
samples were collected at every visit to the outpatient 
clinic. Disease evaluation was performed by CT-scans 
performed approximately every 3 months. Response 
evaluation was performed using RECIST version 1.1 
criteria by a radiologist, unaware of obtained ctDNA 
results. 
All patients gave written informed consent. The 
Medical Ethical Committee approved the study and it is 
registered on ClinicalTrials.gov (NCT02331914).
Tumor sample collection and DNA extraction 
Pre-treatment FFPE tumor biopsies for 27 
consecutive patients diagnosed with exon 11 mutated 
GIST between 2012 and 2015 were retrieved from the 
local pathology archive at the UMCG . Nine GIST tumors 
with mutations outside KIT exon 11 from the same period 
were randomly selected as controls. FFPE samples 
of healthy controls were obtained from the pathology 
department of UMCG. Tumor-specific mutations were 
determined by routine diagnostic NGS of a gene panel 
with relevant predictive markers (version PGMv001; 
www.moloncopath.nl) on the IonTorrent platform 
(Thermo Fisher Scientific, Waltham, MA, USA). The 
analysis of some older tumors was performed using 
Sanger sequencing as reported previously [52].
In brief, two to four 10 µm thick sections were cut 
from the original FFPE blocks preceded and followed by 
a 4 µm section. After haematoxylin and eosin staining, the 
4 µm slides were evaluated by an experienced pathologist 
for the presence of an area with sufficient tumor cells 
(>20%). Genomic DNA from FFPE slides was extracted 
using the Cobas extraction kit (Roche, Basel, Switzerland) 
and quantified using Qubit (Thermo Fisher Scientific). All 
molecular testing was performed in the CCKL/ISO15189-
accredited laboratory of molecular pathology at the 
UMCG. All standard precautions were taken to avoid 
contamination of amplification products using separate 
laboratories for pre- and post-PCR handling. To avoid 
cross-contamination, a new microtome blade was used 
each time a new sample was sectioned. 
Next generation sequencing using IonTorrent 
Libraries were generated using an in-house panel 
(version PGMv001) using the IonTorrent platform. This 
panel consists of 30 primer pairs covering 11 clinically 
relevant genes including hotspots in exon 9, 11, 13 and 
17 of KIT and exon 12, 14 and 18 of PDGFRα (http://
www.moloncopath.nl). 10 ng of DNA from each sample 
was used to prepare barcoded libraries using IonXpress 
barcoded adapters (Thermo Fisher Scientific). Libraries 
were combined to a final concentration of 100 pmol 
using the Ion Library Quantification Kit (Thermo Fisher 
Scientific), and emulsion PCR was performed using 
the IonTorrent OneTouch TM2 system. Samples were 
sequenced on the IonTorrent semi-conductor sequencer 
using Ion 316 or 318 chips. Sequence reads were aligned 
to the 11 genes based on the Human Genome version 19 
using Sequence Pilot v4.2.0 (JSI Medical Systems GmbH, 
Ettenheim, Germany). Also read depth and uniformity of 
coverage across individual amplicons were assessed. In 
data analysis the cut-off was set at mutations found in > 
5% of the reads. Only non-synonymous and non-sense 
variations in coding regions were included. 
Drop-off ddPCR assay 
Since in 80% of the cases exon 11 mutations 
occur in one of the two hotspot regions, one probe 
serves as a wild type probe while the loss of signal 
from the second probe represents the presence of a 
mutation (Figure 3). A ddPCR assay consisting of a 
single set of PCR primers and two TaqMan probes 
(FAM or HEX) was designed using PrimerQuest 
(http://eu.idtdna.com/Primerquest) and purchased 
from IDT (Coralville, IA, USA). The primer sequences 
are Fwd. 5′-CCACAGAAACCCATGTATGAAG-3′ 
(position c.1641-c.1662) and Rev. 5′-GAGTTTCCC 
AGAAACAGGC-3′ (position c.1746-c.1765) resulting 
in a PCR product of 124 base pairs covering both 
hotspots in KIT exon 11 (position c.1641-c.1765, Figure 
3). The sequence of probe I (FAM) is 5′-ACAGT 
GGAAGGTTGTTGAGGAGAT-3′ and probe II (HEX) 
5′-ACCCAACACAACTTCCTTATGATCACA-3′. Tem-
perature gradient PCRs of the primers and probes were 
performed to detect the optimal annealing temperature and 
resulted in an optimal PCR temperature of 60°C. 
Specific ddPCR assays 
For the detection of the c.1676T>A mutation, 
a commercially available assay was purchased 
(dHsaCP2506828 and dHsaCP2506829, Bio-Rad, 
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Hercules, CA, USA). The specific c.1727_1729del assay 
was designed in-house and purchased from IDT. The primer 
sequences are Fwd. 5-′CCACAGAAACCCATGTATG-3′ 
(position c.1643-c.1661) and Rev. 5′-GCCTGTTTC 
TGGGAAAC-3′ (position c.1750-c.1766). The sequence 
of wild type-probe I (FAM) is 5′-ACCCAACACAACC
TTATGATCACAAATG-3′ and mutant-probe II (HEX) 
5′-ACAGTGGAAGGTTGTTGAGGAG-3′. 
DdPCR analysis of DNA of pretreatment tumor 
biopsies 
DdPCR on tumor tissue was performed on 2 ng 
of genomic DNA as measured by Qubit according to 
the manufacturer’s instructions. Briefly, 11 µl ddPCR 
Supermix for probes, 1 µl of the ddPCR assay (wild 
type and mutation primer/probes) and genomic DNA 
were mixed in a final volume of 22 μl. Droplets were 
generated from 20 μl of the suspension using the 
QX100 Droplet generator after addition of 70 μl droplet 
generation oil (Bio-Rad). The PCR was performed on 
a T100 Thermal Cycler (Bio-Rad) using the following 
cycling conditions: 10 minutes at 95° C, 40 cycles of 
95° C for 30 seconds, 60° C for 1 minute followed by 
98° C for 10 minutes (ramp rate 2.5° C/sec). Samples 
were transferred to the QX200 Droplet Reader (Bio-
Rad) for fluorescent measurement of FAM and HEX 
probes and data were analyzed using Quantasoft software 
version 1.6.6. Samples were considered positive when 
3 or more FAM/HEX positive droplets were detected, 
Figure 3: KIT exon 11 mutation/deletion detection assay. (A) When no mutation is present, both probes (FAM and HEX) will 
anneal and droplets with a dual fluorescent signal will be detected (coloured orange in the figure). (B) In cases with a mutation in hotspot 
region I, only droplets with WT region II are detected (HEX, green signal). Also wild type fragments are detected (orange droplets) in the 
graph. (C) Example of a case with a mutation in hotspot region II, only droplets with WT region I are detected (FAM, blue signal). Wild 
type fragments are also detected (orange droplets).
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while no FAM/HEX positive droplets in the no-template 
and no single positive droplets in the wild type controls 
were observed. The fractional abundance is based on 
the ratio between mutant and wild type droplets after 
correction using the Poisson distribution (calculated by 
the Quantasoft software). 
Circulating tumor DNA analysis 
Plasma samples from patients treated at the UMCG 
were collected in EDTA tubes (vacutainer #367525, 
Becton Dickinson, Franklin Lakes, NJ, USA) and 
processed within 4 hours after venipuncture. Samples 
from patients from other centers were collected in cell 
free DNA BCT tubes (Streck, Omaha, NE, USA), which 
stabilizes blood samples for a minimum of 7 days at 
room temperature [53]. The cell free BCT tubes were 
sent by regular mail to the UMCG and processed on the 
day of arrival. For quantitative validation of the assay, 
plasma samples of five anonymous healthy controls were 
collected in the same cell free BCT tubes.
EDTA samples were first centrifuged for 10 
minutes at 820 g to separate the lymphocytes from 
the plasma. The supernatant was transferred to a new 
Eppendorf tube and centrifuged at 16,000 g for 10 
minutes to separate plasma from the remaining debris. 
After the last centrifugation step the supernatant was 
transferred and stored at −80° C until analysis. Cell free 
DNA BCT tubes were processed identically but with 
a different first centrifugation step (1,600 g). Plasma 
processing was performed in a laboratory not used for 
any molecular testing.
For ctDNA isolation, samples were thawed after 
storage at –80° C and centrifuged for 5 minutes at 
16,000 g. DNA was extracted from plasma using the 
QIAamp Circulating Nucleic Acid kit. (QIAgen, Hilden, 
Germany) following manufacturers protocols. DNA 
from 4 ml of plasma was isolated and eluted in 2 × 250 
µl of elution buffer. This eluate was concentrated using 
an Amicon filter column (Merck, Darmstadt, Germany). 
The final amount of eluate was 15–20 µl. After isolation 
the eluate was stored at 4° C until experiments were 
performed. 
The designed drop-off ddPCR assay was used for 
analysis of ctDNA. Experimental conditions were identical 
to those for analysis of tumor tissue except for the input 
per reaction. For analysis of ctDNA the maximum input 
(9 µl) of isolated DNA per reaction was used, each run 
included wild type (WT) and no template controls (NTC). 
The presence of a mutation was calculated as the fractional 
abundance. 
Quantitative L-PCR using 1 ml of cell-free plasma 
was performed as reported in detail previously [22]. 
The laboratory technicians who performed the ddPCR 
experiments were not aware of the mutational and clinical 
status of the tested patient samples. 
Quantitative performance of the drop-off 
ddPCR assay 
The sensitivity of the assay was determined using 
DNA from FFPE pretreatment biopsies with mutations 
in exon 11 hotspot 1 (c.1669T>C and c. 1671_1676del) 
and hotspot 2 (c.1727_1729del) with known mutation 
allelic frequency (MAF) determined by NGS diluted with 
wild type DNA. A significant correlation was observed 
between tumor DNA input as measured by NGS-MAF 
and mutated droplet detection in three different samples 
(Supplementary Figure 4). The limit of detection (LOD) of 
the drop-off ddPCR assay on DNA extracted from FFPE-
tissue with 30 ng DNA input was 0.11% (not shown) and 
with a lower DNA input (2 ng) a maximum of 1% mutant 
alleles was still detected (see example in Supplementary 
Figure 5). 
The limit of blank (LOB, false mutation rate) as 
reported earlier [54] of the ddPCR assays was estimated 
using five FFPE healthy tissue. FFPE samples were tested 
with an input of 2ng and 30ng resulting in respectively in 
a mean of 545 and 5345 wild type droplets and 0 false-
positive droplets per sample (LOB = 0% for tissue DNA). 
To determine the LOB on plasma-derived ctDNA, cell free 
DNA was isolated from five plasma samples of healthy 
controls following the study extraction protocol and 
maximum input was used resulting in a mean of 791 wild 
type droplets and 0 false-positive droplets (LOB = 0% for 
normal plasma DNA, Supplementary Figure 6).
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